Trastuzumab Botidotin Versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A Phase III, Open-Label, Randomized Controlled Trial
Journal of Clinical Oncology · 2026
DOI: 10.1200/jco-26-00602 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, 2026. Verfasst von Jian Zhang und 39 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China. Hauptthemen laut MEDLINE: Ado-Trastuzumab Emtansine, Antineoplastic Agents, Immunological, Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit nennt 27 Literaturangaben.
Abstract (Originalsprache)
PURPOSE To evaluate the safety and efficacy of the novel human epidermal growth factor receptor 2 (HER2)–directed antibody-drug conjugate, trastuzumab botidotin, for the treatment of HER2-positive unresectable/metastatic breast cancer (BC). METHODS In this phase III, open-label, multicenter trial (ClinicalTrials.gov identifier: NCT06968585 ), conducted at 57 centers in China, adult patients with HER2-positive, unresectable/metastatic BC who had received prior trastuzumab and a taxane were randomly assigned (1:1) to receive trastuzumab botidotin or trastuzumab emtansine. The primary end point was progression-free survival (PFS), assessed by blinded independent central review (BICR), using an intention-to-treat analysis. In a prespecified interim analysis of PFS per BICR, trastuzumab botidotin met the prespecified superiority boundary ( P < .0001). We report here the prespecified final analysis of PFS. RESULTS Between July 18, 2023, and April 26, 2024, 365 patients were randomly assigned to trastuzumab botidotin (n = 182) or trastuzumab emtansine (n = 183). At data cutoff (median follow-up, 14.9 months), trastuzumab botidotin resulted in longer PFS than trastuzumab emtansine (median, 11.1 v 4.4 months; hazard ratio [HR], 0.39 [95% CI, 0.30 to 0.51]; nominal P < .0001). Benefit was consistent across subgroups, including those defined by prior lines of anti-HER2 therapy, prior pertuzumab or anti-HER2 tyrosine kinase inhibitors, and visceral metastases. The objective response rate was 76.9% (95% CI, 70.1 to 82.8) with trastuzumab botidotin and 53.0% (95% CI, 45.5 to 60.4) with trastuzumab emtansine. Overall survival data were immature (medians not reached in either group; HR, 0.62 [95% CI, 0.38 to 1.03]). Grade ≥3 treatment-emergent adverse events occurred in 127 (69.8%) and 116 (63.7%) patients in each group, respectively. Ocular treatment-related adverse events had a high incidence with trastuzumab botidotin; however, with a protocol-defined algorithm, most events generally recovered or resolved. Trastuzumab botidotin treatment had low incidences of pulmonary, hematologic, hepatic, and GI toxicities. CONCLUSION Among patients with HER2-positive advanced BC previously treated with trastuzumab and a taxane, trastuzumab botidotin resulted in significantly longer PFS than trastuzumab emtansine, with a distinct safety profile.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
- Breast Internal Medicine Department, Hunan Cancer Hospital, Changsha, China.
- Breast Internal Medicine Ward 1, Harbin Medical University Cancer Hospital, Harbin, China.
- Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
- Department of Breast Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China.
- Breast Internal Medicine Department, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
ORCID-Profile: Jian Zhang, Quchang Ouyang, Yongmei Yin, Shusen Wang, Fanfan Li, Xiaojia Wang, Fan Li, Haijun Yu, Junyou Ge, Xichun Hu
Zitieren
APA
Zhang, J., Ouyang, Q., Zhang, Q., Li, H., Wang, X., Wang, Y., Yin, Y., Wang, S., Gu, Y., Sun, T., Wang, J., Wu, X., Li, F., Chen, X., Li, M., Yang, J., Yang, H., Sun, Z., Nie, J., …, & Hu, X. (2026). Trastuzumab Botidotin Versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A Phase III, Open-Label, Randomized Controlled Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco-26-00602
Vancouver
Zhang J, Ouyang Q, Zhang Q, Li H, Wang X, Wang Y, et al. Trastuzumab Botidotin Versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A Phase III, Open-Label, Randomized Controlled Trial. Journal of Clinical Oncology. 2026. doi:10.1200/jco-26-00602
BibTeX
@article{Zhang2026,
author = {Zhang, Jian and Ouyang, Quchang and Zhang, Qingyuan and Li, Huihui and Wang, Xu and Wang, Ying and Yin, Yongmei and Wang, Shusen and Gu, Yuanting and Sun, Tao and Wang, Jingfen and Wu, Xinhong and Li, Fanfan and Chen, Xi and Li, Man and Yang, Jin and Yang, Hua and Sun, Zhengkui and Nie, Jianyun and Wang, Xiaojia and Liu, Jian and Tang, Xianjun and Wang, Hao and Huang, Zhan and Xie, Weimin and Chen, Wenyan and Li, Fan and Teng, Yuee and Zhang, Shuqun and Zeng, Ru and Wang, Wenhui and Ma, Lixia and Gao, Yongli and Yu, Haijun and Cao, Xiguang and Qing, Yan and Jin, Xiaoping and Ge, Junyou and Wang, Hongxia and Hu, Xichun},
title = {Trastuzumab Botidotin Versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A Phase III, Open-Label, Randomized Controlled Trial},
journal = {Journal of Clinical Oncology},
year = {2026},
doi = {10.1200/jco-26-00602}
}
EUVIMED